Abstract 1181TiP
Background
Melanoma is an aggressive disease with a high propensity to metastasize to the central nervous system. Melanoma brain metastases (MBM) were associated with poor overall survival (OS), with a median OS of 4–5 months before the era of immune checkpoint inhibition (ICI). Nowadays, first-line treatment with BRAF/MEK inhibitors in patients (pts) with BRAFV600 mutated melanoma and MBM induces ∼60% intracranial response, which are unfortunately short-lived. Combined ICI with ipilimumab + nivolumab demonstrated longer-lasting efficacy, but is associated with high rates of toxicity and very limited efficacy in patients with symptomatic MBM. Stereotactic radiosurgery (SRS) for single or multiple lesions is an effective modality to achieve MBM control. Its place upfront or later has not been established. A triplet therapy with BRAF/MEK inhibitors encorafenib (E) + binimetinib (B) and anti-PD-1 monoclonal antibody pembrolizumab (P) is an attractive strategy in BRAFV600 mutated MBM, with a rapid disease response (attributed to E+B) and durable disease control (attributed to P), even in symptomatic MBM, with potentially better tolerability than ipilimumab + nivolumab. This trial aims to test the feasibility of this regimen with or without upfront SRS.
Trial design
This phase II, randomised, controlled, open-label trial assesses the efficacy and safety of adding upfront SRS to E+B+P in the treatment of pts with BRAFV600 mutated melanoma and MBM. Patients are randomly assigned (1:1) to receive (a) E+B+P, or (b) upfront SRS of all cerebral metastases ≥5 mm in diameter, followed by E+B+P. Patients will be treated until disease progression. An amendment to allow previous treatment with anti-PD-1 is ongoing. Using intracranial progression-free survival (IC-PFS) assessed by central review as the primary endpoint, 150 patients will be needed to detect an increase in the median IC-PFS in the SRS + E+B+P arm (HR of 0.60 with 80% power and 2-sided 5% significance level). Secondary endpoints include response rate, disease control, OS, toxicity and quality of life. Exploratory endpoints include predictive factors of response and mechanisms of primary and acquired resistance.
Clinical trial identification
EudraCT n°: 2021-006331-26; NCT04074096.
Editorial acknowledgement
Legal entity responsible for the study
Unicancer.
Funding
Pierre Fabre Médicament.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1100P - Open-label non-randomized phase IB study to characterize the safety, tolerability and recommended dose of tinostamustin in combination with nivolumab in patients with advanced melanoma (ENIGMA)
Presenter: Markus Joerger
Session: Poster session 13
1101P - The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma
Presenter: Jordi Rodon
Session: Poster session 13
1102P - Evaluation of surrogate endpoints for overall survival within the RELATIVITY-047 trial
Presenter: Peter Mohr
Session: Poster session 13
1103P - Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year subgroup analyses from RELATIVITY-047
Presenter: Georgina Long
Session: Poster session 13
1104P - Efficacy of immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD1 treatment: A EUMelareg real-world evidence study
Presenter: Michael Weichenthal
Session: Poster session 13
1105P - First-line nivolumab plus ipilimumab in advanced melanoma patients previously treated with adjuvant systemic therapy
Presenter: Katarzyna Kozak
Session: Poster session 13
1106P - Anti-PD-1 (PD1) monotherapy or in combination with anti-CTLA-4 for metastatic melanoma (MM) patients (pts) with liver metastases (mets)
Presenter: Ines Pires da Silva
Session: Poster session 13
1107P - BRAF mutation status does not impact outcomes with tebentafusp in advanced cutaneous melanoma
Presenter: Alexander Shoushtari
Session: Poster session 13
1108P - Outcomes of patients with unresectable or metastatic melanoma after cessation of immunotherapy following complete response or toxicities
Presenter: Nur Sakinah Zulkifli
Session: Poster session 13